ERBB2 and non-small cell lung carcinoma: JBJ-08–178-01’s ability to reduce both the kinase activity and protein levels of HER2 represents a combination of mechanisms that may lead to better efficacy and tolerance in patients with NSCLC carrying HER2 mutations or amplification [182,184].